Nachman Norwood & Parrott’s Regeneron Pharmaceuticals REGN Stock Holding History

Nachman Norwood & Parrott’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$2.51M	Sell	4,495 -6	-0.1%	-$3.04K	0.26%	77
2021 Q1	$2.13M	Hold	4,501	–	–	0.23%	85
2020 Q4	$2.17M	Sell	4,501 -1	-0%	-$540	0.25%	78
2020 Q3	$2.52M	Hold	4,502	–	–	0.34%	63
2020 Q2	$2.81M	Hold	4,502	–	–	0.46%	42
2020 Q1	$2.2M	Buy	4,502 +75	+2%	+$30.9K	0.44%	49
2019 Q4	$1.66M	Hold	4,427	–	–	0.27%	74
2019 Q3	$1.23M	Sell	4,427 -11	-0.2%	-$3.25K	0.22%	85
2019 Q2	$1.39M	Sell	4,438 -318	-7%	-$106K	0.25%	79
2019 Q1	$1.95M	Sell	4,756 -4	-0.1%	-$1.65K	0.36%	68
2018 Q4	$1.78M	Buy	+4,760	New	+$1.74M	0.37%	65

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Nachman Norwood & Parrott's REGN Position: Q2 2021 in Review

Nachman Norwood & Parrott reduced its Regeneron Pharmaceuticals (REGN) stake by 0.13% in Q2 2021, selling an estimated $3.04K and leaving 4,495 shares worth $2.51M. The position accounts for 0.26% of the portfolio, ranked #77.

Nachman Norwood & Parrott first reported a position in REGN in Q4 2018 and has held it in 11 quarters since. The position peaked at $2.81M in Q2 2020. 972 funds tracked by Wall St. Rank hold REGN as of Q2 2021.

Nachman Norwood & Parrott held 4,495 shares of Regeneron Pharmaceuticals worth $2.51M as of Q2 2021.
Nachman Norwood & Parrott sold 6 Regeneron Pharmaceuticals shares in Q2 2021, an estimated $3.04K.
Regeneron Pharmaceuticals made up 0.26% of Nachman Norwood & Parrott's portfolio in Q2 2021, its #77 holding.
Nachman Norwood & Parrott first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 11 quarters since.
Nachman Norwood & Parrott's Regeneron Pharmaceuticals position peaked at $2.81M in Q2 2020.
972 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2021.

Based on Nachman Norwood & Parrott's 13F filing for Q2 2021, filed 13 Aug 2021.